# Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

> **NCT02584309** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 73 (actual)

## Conditions studied

- Sarcoma, Soft Tissue
- Soft Tissue Sarcoma
- Undifferentiated Pleomorphic Sarcoma
- Leiomyosarcoma
- Liposarcoma
- Synovial Sarcoma
- Myxofibrosarcoma
- Angiosarcoma
- Fibrosarcoma
- Malignant Peripheral Nerve Sheath Tumor
- Epithelioid Sarcoma

## Interventions

- **DRUG:** Dexrazoxane
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT02584309
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-22
- **Primary completion:** 2022-07-17
- **Final completion:** 2022-07-17
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02584309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02584309, "Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02584309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*